Company intelligence / Profile preview

Internis

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Internis was a UK-based specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for bone health and metabolic conditions. The company achieved significant commercial success with its lead product, Fultium-D3, which established itself as a leading prescription Vitamin D3 treatment in the United Kingdom. In addition to bone health, Internis focused on providing cost-effective healthcare solutions to the NHS. The company was acquired by the Swedish pharmaceutical firm Meda in 2014 for an initial consideration of £45 million.

Therapeutic areas: Endocrinology
Modalities: Small moleculeVitamin
Industry: Biotech

Beyond the preview

Go deeper on Internis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Internis.

Explore the full profile